Bifidobacterium longum 用于 Irritable Bowel Syndrome (IBS)
BRCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbifidobacterium\u002Dlongum\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
结论
RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.
Key Study Findings
Meta-Analysis
n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None
vs: placebo
Outcome: quality of life, depression, and anxiety in IBS …
效果: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression)
None
研究人群: patients with irritable bowel syndrome
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
效果: None
None
研究人群: patients with IBS from 32 RCTs evaluating 10 probiotic strains
In Vitro
n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL
vs: IBS supernatants without probiotic
Outcome: Caco-2 paracellular permeability
效果: None
<0.001
研究人群: IBS patients (28) and asymptomatic controls (7)
Review
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Dose: None
vs: None
Outcome: IBS symptom management via NLRP3 inhibition
效果: None
None
研究人群: Patients with IBS (narrative review)
Controlled Clinical Trial
n=51
12 weeks
Open-label
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and …
Dose: None
vs: Pre-treatment baseline
Outcome: IBS-SSS score reduction
效果: None
None
研究人群: IBS-D and IBS-C patients
Observational Study
n=37
8 weeks
Open-label
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms …
Dose: None
vs: None
Outcome: Total IBS symptom score (TISS)
效果: 43.4% TISS reduction; >60% >=30% responders
None
研究人群: Adults with IBS (Rome IV criteria)
Key Statistics
4
研究数量
600
受试者
↑
Positive
B
等级
Referenced Papers
European journal of …
2026
Journal of clinical …
2026
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome.
Observational
Probiotics and antimicrobial …
2025
6 次引用
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Review
Microorganisms
2025
4 次引用
International journal of …
2025
4 次引用
Frontiers in medicine
2025
3 次引用
Gut microbes
2024
22 次引用
Nutrients
2024
13 次引用
Microbiology spectrum
2024
9 次引用
Journal of neurogastroenterology …
2024
4 次引用
Journal of clinical …
2024
4 次引用
Effects of Bifidobacterium longum 35624 in Children and Adolescents with Irritable Bowel Syndrome.
Other
Nutrients
2024
4 次引用
Gut microbes
2024
Journal of translational …
2023
30 次引用
Food & function
2023
18 次引用
Neurogastroenterology and motility
2023
16 次引用
Journal of gastroenterology …
2023
11 次引用
Terapevticheskii arkhiv
2023
3 次引用
Voprosy pitaniia
2023
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome.
Observational
World journal of …
2022
27 次引用
Journal of neurogastroenterology …
2022
21 次引用
Journal of microbiology …
2022
15 次引用
Computational and structural …
2022
15 次引用
Scientific reports
2022
14 次引用
Terapevticheskii arkhiv
2022
6 次引用
Microorganisms
2021
47 次引用
Nutrients
2021
36 次引用
Clinical nutrition ESPEN
2021
11 次引用
Voprosy pitaniia
2021
3 次引用
Gastroenterology
2020
290 次引用
European journal of …
2020
80 次引用
Nutrients
2020
78 次引用
Nutrients
2020
59 次引用
Gut microbes
2020
36 次引用
Journal of clinical …
2020
31 次引用
The Cochrane database …
2020
14 次引用
Nutrients
2019
114 次引用
Beneficial microbes
2019
31 次引用
Journal of neurogastroenterology …
2018
121 次引用
Saudi journal of …
2018
41 次引用
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 次引用
Gastroenterology
2018
23 次引用
Gastroenterology
2017
684 次引用
The Australian and …
2017
280 次引用
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Meta-Analysis
Current medical research …
2017
86 次引用
Journal of gastroenterology …
2017
32 次引用
Current medical research …
2017
21 次引用
PloS one
2016
83 次引用
Artificial cells, nanomedicine, …
2016
16 次引用
Journal of gastroenterology …
2014
164 次引用
Orvosi hetilap
2014
6 次引用
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 次引用
Journal of clinical …
2012
207 次引用
Acta bio-medica : …
2006
41 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 1-10 billion CFU/day
- ibssupport:
- 1 billion CFU/day (35624 strain, marketed as Alflorex/Align)
上限： Well-tolerated up to 10 billion CFU/day in clinical trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | 3154 |
| None | -- | Positive | -- |
| 1e6 CFU/mL | -- | Positive | 35 |
| None | -- | Positive | -- |
| None | 12 weeks | Positive | 51 |
| None | 8 weeks | Positive | 37 |
| 1x10^10 CFU daily | 6 weeks | Positive | 35 |
| 2 g | 4 weeks | Mixed | -- |
最佳服用时间： On an empty stomach or before meals
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional abdominal discomfort
- ⚠ Rare loose stools
- ⚠ Very rare: bacteremia in immunocompromised individuals
已知相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (use with caution in immunocompromised patients)
可耐受最高摄入量： Well-tolerated up to 10 billion CFU/day in clinical trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Bifidobacterium longum help with Irritable Bowel Syndrome (IBS)?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium longum may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium longum should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium longum?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium longum and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Irritable Bowel Syndrome (IBS)
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。